How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
- 1 October 2020
- journal article
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 38 (4), 339-347
- https://doi.org/10.2337/cd20-0014
Abstract
The efficacy and safety of the fixed-ratio combination of insulin degludec (degludec) and liraglutide (IDegLira) were confirmed in the DUAL clinical trial program, in which IDegLira demonstrated superior or noninferior glycemic control over comparators in addition to its low risks of hypoglycemia and weight gain. This article identifies the patient types for whom IDegLira is most appropriate by reviewing the DUAL results and subsequent post hoc analyses and presenting real-world cases in which IDegLira has been used effectively in U.S. clinical practice. In the clinic, IDegLira has been used effectively when patients wanted to avoid more complex injectable regimens, particularly those with renal insufficiency for whom treatment options are limited.Keywords
This publication has 42 references indexed in Scilit:
- A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical RelevanceClinical Pharmacokinetics, 2014
- The rationale for combining GLP‐1 receptor agonists with basal insulinThe Medical Journal of Australia, 2013
- Basal Insulin and Cardiovascular and Other Outcomes in DysglycemiaThe New England Journal of Medicine, 2012
- Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetesDiabetes, Obesity and Metabolism, 2012
- The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetesJournal of Diabetes Investigation, 2012
- Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitusIndian Journal of Endocrinology and Metabolism, 2011
- Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral EndopeptidaseDrug Metabolism and Disposition, 2010
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009